Application Note

An Optimized Platform For pDNA Purification, From Lysis To Sterilizing Grade Filtration For Vaccine Production

By Thomas Parker, Process Development Scientist, Vaccines & Viral Therapies, Technology Management; Youness Cherradi, Senior Process Development Scientist, Technology Management; Niddhivinayak Mishra, Process Development Specialist II, Technology Management – MSAT

DNA and Virus cells iStock-1281238990

Plasmid DNA (pDNA) is an important component of viral vector therapies. These circular double helix DNA molecules can be used as the therapeutic transgene, to code for the viral capsid or as the vaccine itself. DNA vaccines have been approved for use in animals and this approach is being leveraged to combat the SARSCoV-2 virus. In addition, pDNA is used as the starting material for mRNA vaccines which have also emerged in response to the pandemic and have other applications such as oncology. Furthermore, Plasmid DNA constructs are used for mammalian cell transfection to produce viral vectors used in gene therapy.

pDNA manufacturing presents several challenges. Production suffers from low productivity of microbial fermentation and the purification process is complicated by the fact that plasmids are quite large and possess a highly negative charge. The bacterial lysate contains contaminants with properties similar to pDNA leading to low resolution separation and can be highly viscous.

A low flow rate is needed for chromatography and it can be difficult to achieve the desired concentrations at the final tangential flow filtration (TFF) step.

Additionally, pDNA is sensitive to shear stress which can lead to changes in its topological form. Plasmid isoforms include supercoiled (fully intact and wound around itself), open circular (one strand is broken and the molecule relaxes) and linear (both strands are broken with free ends). Supercoiled plasmids are recognized as the most therapeutically relevant and regulatory agencies set expectations for the supercoiled percentage in final drug substance for DNA vaccines.

This paper describes an end-to-end platform consisting of single-use technologies and validation and testing services for pDNA manufacturing. Each of these steps is explored below, along with strategies to optimize and streamline the purification workflow.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: